ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder
ANANDA Scientific Inc ., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial.
Pre-clinical and initial clinical studies show ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd ., Jerusalem, Israel), enhances the effectiveness and stability of CBD. Nantheia™ ATL5 is an oral product with 100mg of CBD per softgel capsule and is ANANDA’s investigational drug utilizing Liquid Structure™ technology.
“This clinical trial with Nantheia™ ATL5 has the possibility to advance applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction. Opioids are a huge driver of overdose deaths in the U.S. and a non-addictive therapy is a significant unmet need,” said Sohail R. Zaidi , ANANDA’s President .
This trial is being conducted at the Icahn School of Medicine at Mount Sinai led by principal investigator Yasmin L Hurd, Ph.D , the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute at Mount Sinai. Funding for this trial was awarded to Dr. Hurd by the National Institute on Drug Abuse (NIDA). (Clinicaltrials.gov Identifier NCT 05203070) .
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications for cannabinoids such as PTSD , Radiculopathic Pain , Anxiety and Opioid Use Disorder . The company employs patented delivery technologies to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa and other countries in Asia planned for the future. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TX-COGNITIVE-SPACE8.12.2021 04:42:05 CET | Press release
Cognitive Space 2021 Recap – Momentum in Artificial Intelligence for Satellite Operations
NCEC8.12.2021 01:03:06 CET | Press release
NCEC and OURAY Announce Integrated Emergency Response Support for the Global Market
TILLOTTS-PHARMA8.12.2021 01:03:06 CET | Press release
Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID
NTT8.12.2021 01:02:05 CET | Press release
NTT: Over 80% of CIOs and Senior Leaders Plan to Deploy Private 5G Networks Within the Next 24 Months
IFBA8.12.2021 00:03:07 CET | Press release
International Food & Beverage Companies Commit to Further Salt Reduction Globally
NORNIR7.12.2021 23:11:11 CET | Press release
Nornir secures €30 Million capital commitment from Global Emerging Markets (GEM)
WORDLEY-PARTNERSHIP7.12.2021 20:51:06 CET | Press release
Wordley Partnership: New Partner Appointments Bolster Insurance, Commercial Litigation, International Arbitration and Corporate Practice
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom